Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABIO ARCA biopharma		$384.99	$1.56 ▼ $4.49	$34.82M	0.91	607,995 shs	290,800 shs
FDMT 4D Molecular Therapeutics	$3.42 -2.0%	$3.24	$2.24 ▼ $28.93	$158.43M	2.87	833,970 shs	293,635 shs
LYEL Lyell Immunopharma	$0.41 -1.8%	$0.45	$0.39 ▼ $2.85	$121.27M	-0.25	1.03 million shs	461,663 shs
SCPH scPharmaceuticals	$3.54 +6.9%	$2.65	$1.94 ▼ $5.65	$186.88M	0.17	366,831 shs	291,959 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABIO ARCA biopharma	0.00%	0.00%	0.00%	0.00%	-99.51%
FDMT 4D Molecular Therapeutics	0.00%	-8.16%	+4.49%	-23.13%	-86.12%
LYEL Lyell Immunopharma	0.00%	+1.21%	-7.13%	-36.84%	-84.91%
SCPH scPharmaceuticals	0.00%	-5.97%	+31.87%	-0.30%	-5.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	2.9134 of 5 stars	4.3	2.0	0.0	0.0	2.7	1.7	0.6
LYEL Lyell Immunopharma	3.0498 of 5 stars	2.8	2.0	0.0	0.0	3.2	5.0	1.3
SCPH scPharmaceuticals	4.1336 of 5 stars	3.5	4.0	0.0	4.2	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABIO ARCA biopharma	0.00	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	764.20% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$1.00	143.55% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	295.48% Upside

Current Analyst Ratings Breakdown

Latest ABIO, FDMT, SCPH, and LYEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/16/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/20/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $12.00
3/20/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	$2.25 per share	N/A
FDMT 4D Molecular Therapeutics	$23K	6,888.33	N/A	N/A	$7.20 per share	0.48
LYEL Lyell Immunopharma	$65K	1,865.63	N/A	N/A	$2.60 per share	0.16
SCPH scPharmaceuticals	$41.98M	4.45	N/A	N/A	$1.04 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABIO ARCA biopharma	-$5.34M	-$0.42	N/A	N/A	N/A	N/A	-20.18%	-19.51%	N/A
FDMT 4D Molecular Therapeutics	-$100.84M	-$3.18	N/A	N/A	N/A	N/A	-28.00%	-26.16%	8/14/2025 (Estimated)
LYEL Lyell Immunopharma	-$234.63M	-$1.25	N/A	N/A	N/A	-323,792.09%	-34.64%	-30.02%	8/6/2025 (Estimated)
SCPH scPharmaceuticals	-$54.81M	-$1.91	N/A	N/A	N/A	-264.60%	-244.93%	-68.56%	8/13/2025 (Estimated)

Latest ABIO, FDMT, SCPH, and LYEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$0.19	-$0.18	+$0.01	-$0.18	N/A	$0.01 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million
3/12/2025	Q4 2024	LYEL Lyell Immunopharma	-$0.20	-$0.72	-$0.52	-$0.72	N/A	$0.01 million
2/28/2025	Q4 2024	FDMT 4D Molecular Therapeutics	-$0.80	-$0.90	-$0.10	-$0.90	$2.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABIO ARCA biopharma	N/A	26.61	26.61
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
LYEL Lyell Immunopharma	N/A	13.43	13.43
SCPH scPharmaceuticals	1.66	8.08	6.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABIO ARCA biopharma	56.44%
FDMT 4D Molecular Therapeutics	99.27%
LYEL Lyell Immunopharma	66.05%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
ABIO ARCA biopharma	30.90%
FDMT 4D Molecular Therapeutics	9.60%
LYEL Lyell Immunopharma	25.10%
SCPH scPharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABIO ARCA biopharma	6	14.51 million	10.02 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	42.85 million	Optionable
LYEL Lyell Immunopharma	270	295.34 million	218.83 million	Optionable
SCPH scPharmaceuticals	30	52.79 million	47.28 million	Optionable

ABIO, FDMT, SCPH, and LYEL Headlines

Recent News About These Companies

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

Stonepine Capital Management LLC Has $2.42 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 20, 2025 | marketbeat.com

Leerink Partnrs Has Bearish Forecast for SCPH Q2 Earnings

May 20, 2025 | americanbankingnews.com

Leerink Partnrs Analysts Lower Earnings Estimates for SCPH

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Reduces Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 19, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for SCPH FY2027 Earnings?

May 18, 2025 | americanbankingnews.com

What is HC Wainwright's Forecast for SCPH Q1 Earnings?

May 18, 2025 | americanbankingnews.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Stake Reduced by J. Goldman & Co LP

May 14, 2025 | marketbeat.com

Insights Ahead: scPharmaceuticals's Quarterly Earnings

May 13, 2025 | benzinga.com

scPharmaceuticals (SCPH) Expected to Announce Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABIO, FDMT, SCPH, and LYEL Company Descriptions

ARCA biopharma NASDAQ:ABIO

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

4D Molecular Therapeutics NASDAQ:FDMT

$3.42 -0.07 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 0.00 (0.00%)

As of 04:22 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Lyell Immunopharma NASDAQ:LYEL

$0.41 -0.01 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.43 +0.02 (+4.24%)

As of 06:31 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

scPharmaceuticals NASDAQ:SCPH

$3.54 +0.23 (+6.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.54 0.00 (-0.14%)

As of 05:21 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time